EW Stock Recent News

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.

IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.

The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of.

Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.

Edwards Lifesciences' EW stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.

Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday.

Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Larry Wood - Corporate VP and Group President of TAVR & Surgical Structural Heart Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Christopher Pasquale - Nephron Research LLC Operator Greetings, and welcome to the Edwards Lifesciences Second

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.